Expanding Antiretroviral Options in Resource-Limited Settings-A Cost-Effectiveness Analysis
Authors:
- Eran BendavidEBEran Bendavid
- Robin WoodRWRobin Wood
- David A KatzensteinDKDavid A Katzenstein
- Ahmed M Md BayoumiABAhmed M Md Bayoumi
- Douglas K OwensDODouglas K Owens
- 1 September 2009
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 52 (1) , 106-113
Abstract
Background: Current World Health Organization (WHO) guidelines for treatment of HIV in resource-limited settings call for 2 antiretroviral regimens. The effectiveness and cost-effectiveness of increasing the number of antiretroviral regimens is unknown. Methods: Using a simulation model, we compared the survival and costs of current WHO regimens with two 3-regimen strategies: an initial regimen of 3 nucleoside reverse transcriptase inhibitors followed by the WHO regimens and the WHO regimens followed by a regimen with a second-generation boosted protease inhibitor (2bPI). We evaluated monitoring with CD4 counts only and with both CD4 counts and viral load. We used cost and effectiveness data from Cape Town and tested all assumptions in sensitivity analyses. Results: Over the lifetime of the cohort, 25.6% of individuals failed both WHO regimens by virologic criteria. However, when patients were monitored using CD4 counts alone, only 6.5% were prescribed additional highly active antiretroviral therapy due to missed and delayed detection of failure. The life expectancy gain for individuals who took a 2bPI was 6.7-8.9 months, depending on the monitoring strategy. When CD4 alone was available, adding a regimen with a 2bPI was associated with an incremental cost-effectiveness ratio of $2581 per year of life gained, and when viral load was available, the ratio was $6519 per year of life gained. Strategies with triple-nucleoside reverse transcriptase inhibitor regimens in initial therapy were dominated. Results were sensitive to the price of 2bPIs. Conclusions: About 1 in 4 individuals who start highly active antiretroviral therapy in sub-Saharan Africa will fail currently recommended regimens. At current prices, adding a regimen with a 2bPI is cost effective for South Africa and other middle-income countries by WHO standards.Keywords
This publication has 41 references indexed in Scilit:
- Cost-effectiveness of HIV Monitoring Strategies in Resource-Limited SettingsArchives of internal medicine (1960), 2008
- Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation modelThe Lancet, 2008
- A wake-up call for global access to salvage HIV drug regimensThe Lancet, 2007
- HIV-1 viral load testing cost in developing countries: what’s new?Expert Review of Molecular Diagnostics, 2007
- Faculty Opinions recommendation of Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort.2007
- Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trialThe Lancet, 2007
- Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppressionAIDS, 2007
- Conservation of First-Line Antiretroviral Treatment Regimen where Therapeutic Options are LimitedAntiviral Therapy, 2007
- Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in AfricaAIDS, 2006
- Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 InfectionNew England Journal of Medicine, 2004